Pharmosa Biopharm Inc. (TPEX:6875)
Taiwan · Delayed Price · Currency is TWD 32.30
-0.70 (-2.12%)
Sep 8, 2026, 1:30 PM CST
Pharmosa Biopharm Revenue
Pharmosa Biopharm had revenue of 53.38M TWD in the twelve months ending June 30, 2026, down -69.26% year-over-year. In the year 2025, Pharmosa Biopharm had annual revenue of 67.27M, down -59.86%.
Revenue (ttm)
53.38M
Revenue Growth
-69.26%
P/S Ratio
79.37
Revenue / Employee
n/a
Employees
40
Market Cap
4.24B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 67.27M | -100.30M | -59.86% |
| Dec 31, 2024 | 167.57M | -146.93M | -46.72% |
| Dec 31, 2023 | 314.50M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apex Biotechnology | 1.87B |
| SYN-TECH Chem. & Pharm. | 1.27B |
| Medigen Biotechnology | 1.27B |
| Mycenax Biotech | 815.87M |
| BioGend Therapeutics | 236.58M |
| Formosa Pharmaceuticals | 52.59M |
| OBI Pharma | 52.20M |
| UnicoCell Biomed | 22.46M |